Skip to main content
Top
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Sarcopenia | Research

Association of low muscle mass with cognitive function and mortality in USA seniors: results from NHANES 1999–2002

Authors: Yinghui Wang, Dongmei Mu, Yuehui Wang

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

Sarcopenia and cognitive impairment have been linked in prior research, and both are linked to an increased risk of mortality in the general population. Muscle mass is a key factor in the diagnosis of sarcopenia. The relationship between low muscle mass and cognitive function in the aged population, and their combined impact on the risk of death in older adults, is currently unknown. This study aimed to explore the correlation between low muscle mass and cognitive function in the older population, and the relationship between the two and mortality in older people.

Methods

Data were from the National Health and Nutrition Examination Survey 1999–2002. A total of 2540 older adults aged 60 and older with body composition measures were included. Specifically, 17–21 years of follow-up were conducted on every participant. Low muscle mass was defined using the Foundation for the National Institute of Health and the Asian Working Group for Sarcopenia definitions: appendicular lean mass (ALM) (< 19.75 kg for males; <15.02 kg for females); or ALM divided by body mass index (BMI) (ALM: BMI, < 0.789 for males; <0.512 for females); or appendicular skeletal muscle mass index (ASMI) (< 7.0 kg/m2 for males; <5.4 kg/m2 for females). Cognitive functioning was assessed by the Digit Symbol Substitution Test (DSST). The follow-up period was calculated from the NHANES interview date to the date of death or censoring (December 31, 2019).

Results

We identified 2540 subjects. The mean age was 70.43 years (43.3% male). Age-related declines in DSST scores were observed. People with low muscle mass showed lower DSST scores than people with normal muscle mass across all age groups, especially in the group with low muscle mass characterized by ALM: BMI (60–69 years: p < 0.001; 70–79 years: p < 0.001; 80 + years: p = 0.009). Low muscle mass was significantly associated with lower DSST scores after adjusting for covariates (ALM: 43.56 ± 18.36 vs. 47.56 ± 17.44, p < 0.001; ALM: BMI: 39.88 ± 17.51 vs. 47.70 ± 17.51, p < 0.001; ASMI: 41.07 ± 17.89 vs. 47.42 ± 17.55, p < 0.001). At a mean long-term follow-up of 157.8 months, those with low muscle mass were associated with higher all-cause mortality (ALM: OR 1.460, 95% CI 1.456–1.463; ALM: BMI: OR 1.452, 95% CI 1.448–1.457); ASMI: OR 3.075, 95% CI 3.063–3.088). In the ALM: BMI and ASMI-defined low muscle mass groups, participants with low muscle mass and lower DSST scores were more likely to incur all-cause mortality ( ALM: BMI: OR 0.972, 95% CI 0.972–0.972; ASMI: OR 0.957, 95% CI 0.956–0.957).

Conclusions

Low muscle mass and cognitive function impairment are significantly correlated in the older population. Additionally, low muscle mass and low DSST score, alone or in combination, could be risk factors for mortality in older adults.
Appendix
Available only for authorised users
Literature
2.
go back to reference Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing. 2010;39:412–23.CrossRefPubMedPubMedCentral Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing. 2010;39:412–23.CrossRefPubMedPubMedCentral
3.
go back to reference Correa-de-Araujo R, Harris-Love MO, Miljkovic I, Fragala MS, Anthony BW, Manini TM. The need for standardized assessment of muscle quality in skeletal muscle function deficit and other aging-related muscle dysfunctions: a symposium report. Front Physiol. 2017;8:87.CrossRefPubMedPubMedCentral Correa-de-Araujo R, Harris-Love MO, Miljkovic I, Fragala MS, Anthony BW, Manini TM. The need for standardized assessment of muscle quality in skeletal muscle function deficit and other aging-related muscle dysfunctions: a symposium report. Front Physiol. 2017;8:87.CrossRefPubMedPubMedCentral
4.
go back to reference Zamboni M, Rubele S, Rossi AP. Sarcopenia and obesity. Curr Opin Clin Nutr Metabo Care. 2019;22:13–9.CrossRef Zamboni M, Rubele S, Rossi AP. Sarcopenia and obesity. Curr Opin Clin Nutr Metabo Care. 2019;22:13–9.CrossRef
5.
go back to reference Larsson L, Degens H, Li M, Salviati L, Lee YI, Thompson W, et al. Sarcopenia: aging-related loss of muscle Mass and function. Physiol Rev. 2019;99:427–511.CrossRefPubMed Larsson L, Degens H, Li M, Salviati L, Lee YI, Thompson W, et al. Sarcopenia: aging-related loss of muscle Mass and function. Physiol Rev. 2019;99:427–511.CrossRefPubMed
6.
go back to reference Picca A, Calvani R, Bossola M, Allocca E, Menghi A, Pesce V, et al. Update on mitochondria and muscle aging: all wrong roads lead to sarcopenia. Biol Chem. 2018;399:421–36.CrossRefPubMed Picca A, Calvani R, Bossola M, Allocca E, Menghi A, Pesce V, et al. Update on mitochondria and muscle aging: all wrong roads lead to sarcopenia. Biol Chem. 2018;399:421–36.CrossRefPubMed
7.
go back to reference Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69:547–58.CrossRefPubMedPubMedCentral Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69:547–58.CrossRefPubMedPubMedCentral
8.
go back to reference Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21:300-307.e2.CrossRefPubMed Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21:300-307.e2.CrossRefPubMed
11.
go back to reference Rosano C, Newman AB, Katz R, Hirsch CH, Kuller LH. Association between lower digit symbol substitution test score and slower gait and greater risk of mortality and of developing incident disability in well-functioning older adults. J Am Geriatr Soc. 2008;56:1618–25.CrossRefPubMedPubMedCentral Rosano C, Newman AB, Katz R, Hirsch CH, Kuller LH. Association between lower digit symbol substitution test score and slower gait and greater risk of mortality and of developing incident disability in well-functioning older adults. J Am Geriatr Soc. 2008;56:1618–25.CrossRefPubMedPubMedCentral
12.
go back to reference Adjoian Mezzaca T, Dodds LV, Rundek T, Zeki Al Hazzouri A, Caunca MR, Gomes-Osman J, et al. Associations between cognitive functioning and mortality in a population-based sample of older United States adults: differences by sex and education. J Aging Health. 2022;34:905–15.CrossRefPubMed Adjoian Mezzaca T, Dodds LV, Rundek T, Zeki Al Hazzouri A, Caunca MR, Gomes-Osman J, et al. Associations between cognitive functioning and mortality in a population-based sample of older United States adults: differences by sex and education. J Aging Health. 2022;34:905–15.CrossRefPubMed
13.
go back to reference Hart RP, Kwentus JA, Wade JB, Hamer RM. Digit symbol performance in mild dementia and depression. J Consult Clin Psychol. 1987;55:236–8.CrossRefPubMed Hart RP, Kwentus JA, Wade JB, Hamer RM. Digit symbol performance in mild dementia and depression. J Consult Clin Psychol. 1987;55:236–8.CrossRefPubMed
14.
go back to reference Haase CB, Brodersen JB, Bülow J. Sarcopenia: early prevention or overdiagnosis? BMJ. 2022;376:e052592.CrossRefPubMed Haase CB, Brodersen JB, Bülow J. Sarcopenia: early prevention or overdiagnosis? BMJ. 2022;376:e052592.CrossRefPubMed
15.
go back to reference Jaeger J. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharm. 2018;38:513–9.CrossRef Jaeger J. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharm. 2018;38:513–9.CrossRef
16.
go back to reference Brody DJ, Kramarow EA, Taylor CA, McGuire LC. Cognitive performance in adults aged 60 and over: National Health and Nutrition Examination Survey, 2011–2014. Natl Health Stat Rep. 2019;126:1–23. Brody DJ, Kramarow EA, Taylor CA, McGuire LC. Cognitive performance in adults aged 60 and over: National Health and Nutrition Examination Survey, 2011–2014. Natl Health Stat Rep. 2019;126:1–23.
17.
go back to reference Gong HJ, Tang X, Chai YH, Qiao YS, Xu H, Patel I, et al. Predicted lean body mass in relation to cognitive function in the older adults. Front Endocrinol (Lausanne). 2023;14:1172233.CrossRefPubMed Gong HJ, Tang X, Chai YH, Qiao YS, Xu H, Patel I, et al. Predicted lean body mass in relation to cognitive function in the older adults. Front Endocrinol (Lausanne). 2023;14:1172233.CrossRefPubMed
18.
go back to reference Someya Y, Tamura Y, Kaga H, Sugimoto D, Kadowaki S, Suzuki R, et al. Sarcopenic obesity is associated with cognitive impairment in community-dwelling older adults: the Bunkyo Health Study. Clin Nutr. 2022;41:1046–51.CrossRefPubMed Someya Y, Tamura Y, Kaga H, Sugimoto D, Kadowaki S, Suzuki R, et al. Sarcopenic obesity is associated with cognitive impairment in community-dwelling older adults: the Bunkyo Health Study. Clin Nutr. 2022;41:1046–51.CrossRefPubMed
19.
go back to reference Hu Y, Peng W, Ren R, Wang Y, Wang G. Sarcopenia and mild cognitive impairment among elderly adults: the first longitudinal evidence from CHARLS. J Cachexia Sarcopenia Muscle. 2022;13:2944–52.CrossRefPubMedPubMedCentral Hu Y, Peng W, Ren R, Wang Y, Wang G. Sarcopenia and mild cognitive impairment among elderly adults: the first longitudinal evidence from CHARLS. J Cachexia Sarcopenia Muscle. 2022;13:2944–52.CrossRefPubMedPubMedCentral
20.
go back to reference Peng T-C, Chen W-L, Wu L-W, Chang Y-W, Kao T-W. Sarcopenia and cognitive impairment: a systematic review and meta-analysis. Clin Nutr. 2020;39:2695–701.CrossRefPubMed Peng T-C, Chen W-L, Wu L-W, Chang Y-W, Kao T-W. Sarcopenia and cognitive impairment: a systematic review and meta-analysis. Clin Nutr. 2020;39:2695–701.CrossRefPubMed
21.
go back to reference Fhon JRS, Silva ARF, Lima EFC, Santos Neto APD, Henao-Castaño ÁM, Fajardo-Ramos E, et al. Association between sarcopenia, falls, and cognitive impairment in older people: a systematic review with meta-analysis. Int J Env Res Pub He. 2023;20:4156.CrossRef Fhon JRS, Silva ARF, Lima EFC, Santos Neto APD, Henao-Castaño ÁM, Fajardo-Ramos E, et al. Association between sarcopenia, falls, and cognitive impairment in older people: a systematic review with meta-analysis. Int J Env Res Pub He. 2023;20:4156.CrossRef
22.
go back to reference Yang Y, Xiao M, Leng L, Jiang S, Feng L, Pan G, et al. A systematic review and meta-analysis of the prevalence and correlation of mild cognitive impairment in sarcopenia. J Cachexia Sarcopenia Muscle. 2023;14:45–56.CrossRefPubMed Yang Y, Xiao M, Leng L, Jiang S, Feng L, Pan G, et al. A systematic review and meta-analysis of the prevalence and correlation of mild cognitive impairment in sarcopenia. J Cachexia Sarcopenia Muscle. 2023;14:45–56.CrossRefPubMed
23.
go back to reference Chen X, Cao M, Liu M, Liu S, Zhao Z, Chen H. Association between sarcopenia and cognitive impairment in the older people: a meta-analysis. Eur Geriatr Med. 2022;13:771–87.CrossRefPubMed Chen X, Cao M, Liu M, Liu S, Zhao Z, Chen H. Association between sarcopenia and cognitive impairment in the older people: a meta-analysis. Eur Geriatr Med. 2022;13:771–87.CrossRefPubMed
24.
go back to reference Moon JH, Moon JH, Kim KM, Choi SH, Lim S, Park KS, et al. Sarcopenia as a predictor of future cognitive impairment in older adults. J Nutr Health Aging. 2016;20:496–502.CrossRefPubMed Moon JH, Moon JH, Kim KM, Choi SH, Lim S, Park KS, et al. Sarcopenia as a predictor of future cognitive impairment in older adults. J Nutr Health Aging. 2016;20:496–502.CrossRefPubMed
25.
go back to reference Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial. JAMA. 2015;314:781–90.CrossRefPubMedPubMedCentral Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial. JAMA. 2015;314:781–90.CrossRefPubMedPubMedCentral
26.
go back to reference Beaudart C, Sanchez-Rodriguez D, Locquet M, Reginster J-Y, Lengelé L, Bruyère O. Malnutrition as a strong predictor of the onset of Sarcopenia. Nutrients. 2019;11:2883.CrossRefPubMedPubMedCentral Beaudart C, Sanchez-Rodriguez D, Locquet M, Reginster J-Y, Lengelé L, Bruyère O. Malnutrition as a strong predictor of the onset of Sarcopenia. Nutrients. 2019;11:2883.CrossRefPubMedPubMedCentral
28.
29.
go back to reference Zhang H, Lin S, Gao T, Zhong F, Cai J, Sun Y, et al. Association between sarcopenia and metabolic syndrome in middle-aged and older non-obese adults: a systematic review and meta-analysis. Nutrients. 2018;10:364.CrossRefPubMedPubMedCentral Zhang H, Lin S, Gao T, Zhong F, Cai J, Sun Y, et al. Association between sarcopenia and metabolic syndrome in middle-aged and older non-obese adults: a systematic review and meta-analysis. Nutrients. 2018;10:364.CrossRefPubMedPubMedCentral
30.
go back to reference Erickson KI, Donofry SD, Sewell KR, Brown BM, Stillman CM. Cognitive aging and the promise of physical activity. Annu Rev Clin Psycho. 2022;18:417–42.CrossRef Erickson KI, Donofry SD, Sewell KR, Brown BM, Stillman CM. Cognitive aging and the promise of physical activity. Annu Rev Clin Psycho. 2022;18:417–42.CrossRef
31.
go back to reference Arosio B, Calvani R, Ferri E, Coelho-Junior HJ, Carandina A, Campanelli F, et al. Sarcopenia and cognitive decline in older adults: targeting the muscle-brain axis. Nutrients. 2023;15:1853.CrossRefPubMedPubMedCentral Arosio B, Calvani R, Ferri E, Coelho-Junior HJ, Carandina A, Campanelli F, et al. Sarcopenia and cognitive decline in older adults: targeting the muscle-brain axis. Nutrients. 2023;15:1853.CrossRefPubMedPubMedCentral
32.
go back to reference Chou M-Y, Nishita Y, Nakagawa T, Tange C, Tomida M, Shimokata H, et al. Role of gait speed and grip strength in predicting 10-year cognitive decline among community-dwelling older people. BMC Geriatr. 2019;19:186.CrossRefPubMedPubMedCentral Chou M-Y, Nishita Y, Nakagawa T, Tange C, Tomida M, Shimokata H, et al. Role of gait speed and grip strength in predicting 10-year cognitive decline among community-dwelling older people. BMC Geriatr. 2019;19:186.CrossRefPubMedPubMedCentral
33.
go back to reference Amini N, Dupont J, Lapauw L, Vercauteren L, Antonio L, O’Neill TW, et al. Sarcopenia-defining parameters, but not Sarcopenia, are associated with cognitive domains in middle-aged and older European men. J Cachexia Sarcopenia Muscle. 2023;14:1520–32.CrossRefPubMedPubMedCentral Amini N, Dupont J, Lapauw L, Vercauteren L, Antonio L, O’Neill TW, et al. Sarcopenia-defining parameters, but not Sarcopenia, are associated with cognitive domains in middle-aged and older European men. J Cachexia Sarcopenia Muscle. 2023;14:1520–32.CrossRefPubMedPubMedCentral
34.
go back to reference Proust-Lima C, Amieva H, Dartigues J-F, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol. 2007;165:344–50.CrossRefPubMed Proust-Lima C, Amieva H, Dartigues J-F, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol. 2007;165:344–50.CrossRefPubMed
35.
go back to reference Thirumala PD, Reddy RP, Lopez OL, Chang YF, Becker JT, Kuller LH. Long-term cognitive decline and mortality after carotid endarterectomy. Clin Neurol Neurosur. 2020;194:105823.CrossRef Thirumala PD, Reddy RP, Lopez OL, Chang YF, Becker JT, Kuller LH. Long-term cognitive decline and mortality after carotid endarterectomy. Clin Neurol Neurosur. 2020;194:105823.CrossRef
36.
go back to reference Rosano C, Chang Y-F, Kuller LH, Guralnik JM, Studenski SA, Aizenstein HJ, et al. Long-term survival in adults 65 years and older with white matter hyperintensity: association with performance on the digit symbol substitution test. Psychosom Med. 2013;75:624–31.CrossRefPubMed Rosano C, Chang Y-F, Kuller LH, Guralnik JM, Studenski SA, Aizenstein HJ, et al. Long-term survival in adults 65 years and older with white matter hyperintensity: association with performance on the digit symbol substitution test. Psychosom Med. 2013;75:624–31.CrossRefPubMed
Metadata
Title
Association of low muscle mass with cognitive function and mortality in USA seniors: results from NHANES 1999–2002
Authors
Yinghui Wang
Dongmei Mu
Yuehui Wang
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Sarcopenia
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-024-05035-9

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine